Clinical trials
HPV Positive Oropharyngeal Squamous Cell Carcinoma clinical trials
Below are recruiting hpv positive oropharyngeal squamous cell carcinoma clinical trials, each written for real people, not researchers. We’re tracking 81 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07139990RecruitingPhase 1
Personalized radiotherapy for lung, brain, sarcoma, or head and neck cancers
This trial tests whether giving personalized radiotherapy alongside standard treatments can better control several types of cancer: small cell lung cancer, brain metastases, soft tissue sarcoma, and head and neck cancer. It aims to see if this approach helps patients live longer without their cancer growing or coming back.
Dallas, TexasAges 18 years+ - NCT03526835RecruitingPhase 1/Phase 2
Study of MCLA-158 for advanced solid tumors
This trial tests a new experimental drug called MCLA-158 (petosemtamab) for people with advanced solid tumors, especially head and neck cancer or colorectal cancer, that have not responded to standard treatments. The study aims to see if this drug can shrink tumors or slow their growth.
La Jolla, CaliforniaAges 18 years+ - NCT05446467RecruitingPhase 2
Pembrolizumab before surgery for advanced head and neck cancer
This trial studies whether pembrolizumab, given before surgery, can improve outcomes for certain people with stage III–IVA head and neck squamous cell cancer. It’s typically added alongside low-dose PFAS as part of treatment leading up to standard surgery and afterward medicines/radiation.
Qingdao, ShandongAges 18–85 - NCT06607406Recruiting
Timing of radiation after surgery for head and neck cancer
This study tests whether starting radiation therapy more than 6 weeks (but within 16 weeks) after surgery is safe and effective for people with certain high-risk head and neck cancers. It could help those who had to delay radiation for recovery or other reasons.
Charlotte, North CarolinaAges 18 years+ - NCT06385080RecruitingPhase 1/Phase 2
Study of amivantamab for head and neck cancer
This trial tests a drug called amivantamab, either alone or with other treatments, for people with head and neck cancer that has spread or come back. The goal is to see if the drug can help shrink tumors or control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT07264075RecruitingPhase 3
Ivonescimab with or without ligufalimab vs pembrolizumab for head and neck cancer
This trial tests a new immunotherapy combination (ivonescimab alone or with ligufalimab) against the standard immunotherapy pembrolizumab (Keytruda) for people with head and neck cancer that has come back or spread. It may be an option if you have not had any prior immunotherapy and your tumor is PD-L1 positive.
Le HavreAges 18–80 - NCT07290621RecruitingPhase 2
Toripalimab with standard treatment for HPV-positive throat cancer
This study tests adding a new immunotherapy drug (toripalimab) to standard chemo for HPV-positive throat cancer. It aims to see if this combination works better than chemo alone for patients whose cancer has spread to nodes but not to other parts of the body.
Chicago, IllinoisAges 18 years+ - NCT06254911RecruitingPhase 2
Immunotherapy before surgery for HPV-related throat cancer
This trial tests whether giving the drug atezolizumab before surgery can help shrink HPV-related throat cancer and improve outcomes. Atezolizumab helps your immune system fight cancer cells.
Atlanta, GeorgiaAges 18 years+ - NCT06741982RecruitingPhase 1
Immune-targeted therapy and virus treatment before head and neck cancer surgery
This trial tests a combination of immune therapy, targeted drugs, and a virus-based treatment before surgery for head and neck cancer that has spread to lymph nodes. The goal is to see if this approach can shrink the tumor and improve outcomes.
Chengdu, SichuanAges 18–70
Hear when a new HPV Positive Oropharyngeal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hpv positive oropharyngeal squamous cell carcinoma?
- Yes. Clin2 currently lists 81 recruiting hpv positive oropharyngeal squamous cell carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hpv positive oropharyngeal squamous cell carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hpv positive oropharyngeal squamous cell carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Oropharyngeal Squamous Cell Carcinoma
- HPV-Related Squamous Cell Carcinoma
- Recurrent Oropharyngeal Squamous Cell Carcinoma
- HPV-Related Anal Squamous Cell Carcinoma
- Metastatic Oropharyngeal Squamous Cell Carcinoma
- Oropharyngeal Squamous Cell Carcinoma (SCC)
- HPV-Negative Squamous Cell Carcinoma
- HPV-Related Penile Squamous Cell Carcinoma
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.